Diabetic peripheral neuropathy is the complication that destroys feet — slowly, quietly, and often without much warning. It damages the nerves in your extremities until you can no longer feel cuts, blisters, or pressure sores, and those unnoticed injuries become ulcers that refuse to heal. The lifetime risk of developing a diabetic foot ulcer sits between 19% and 34%, and these ulcers precede 80% of lower-extremity amputations in people with diabetes. For the estimated 18.6 million people worldwide dealing with a diabetic foot ulcer in any given year, the stakes are not abstract.
As for the drug that helps — there is no single miracle fix, but a class of medications called GLP-1 receptor agonists, particularly semaglutide, is showing striking promise. A 2025 database study found semaglutide users had an amputation rate of just 2.34% compared to 5.21% among non-users, alongside significantly fewer chronic non-healing wounds. This article is written for a brain health audience for good reason: diabetes damages nerves everywhere, not just in the feet, and the same metabolic dysfunction that causes peripheral neuropathy also accelerates cognitive decline and raises dementia risk. Understanding what happens in the feet offers a window into what is happening throughout the entire nervous system. Below, we cover the full scope of diabetic peripheral neuropathy — the numbers behind its devastation, the FDA-approved treatments for neuropathic pain, the emerging research on GLP-1 drugs and wound healing, and what new therapies are in the pipeline.
Table of Contents
- How Does Diabetes Destroy Your Feet — And Why Is It So Hard to Stop?
- What Are the FDA-Approved Drugs for Diabetic Neuropathy Pain?
- Why GLP-1 Drugs Like Semaglutide Are Changing the Equation for Diabetic Feet
- Comparing Treatment Options — What Actually Works and For Whom
- The Recurrence Problem — Why Healing a Foot Ulcer Is Only Half the Battle
- New Devices and Pipeline Drugs to Watch
- The Bigger Picture — Diabetic Neuropathy as a Whole-Body Nerve Problem
- Conclusion
- Frequently Asked Questions
How Does Diabetes Destroy Your Feet — And Why Is It So Hard to Stop?
Diabetic peripheral neuropathy is the most frequent complication of diabetes, eventually affecting 60% to 70% of everyone who has the disease. It works through a grim sequence. Chronically elevated blood sugar damages small blood vessels and nerve fibers, particularly in the longest nerves — the ones running to the feet. Once those nerves stop functioning properly, sensation dulls or disappears entirely. A person might step on a nail, develop a blister from an ill-fitting shoe, or burn their foot in a hot bath, and feel nothing. The resulting wound, deprived of normal blood flow and immune response by the same diabetic vascular damage, struggles to close. Only 30% to 40% of diabetic foot ulcers heal at 12 weeks. What makes this especially cruel is the recurrence rate. Even when a foot ulcer does heal, 42% come back within one year.
At five years, that number climbs to 65%. Meanwhile, 50% to 60% of ulcers become infected at some point, and roughly 20% of moderate-to-severe infections lead to amputation. The lifetime incidence of lower-extremity amputation for someone in this cycle is 20%, and the five-year mortality rate after amputation — 50% to 70% — exceeds that of many cancers. These are not rare outcomes. These are the expected trajectory for a large portion of the diabetic population. To compare: a diagnosis of colon cancer has a five-year survival rate of about 65%. A major diabetic amputation is statistically worse. Yet foot complications rarely receive the public alarm they warrant. In some regions, amputation rates have actually increased by as much as 50% in recent years after a long period of decline, with the sharpest rises occurring in young adults and minority populations — groups less likely to have consistent access to preventive podiatric care.
What Are the FDA-Approved Drugs for Diabetic Neuropathy Pain?
The pain from diabetic peripheral neuropathy can range from a persistent burning or tingling to episodes of sharp, stabbing agony. Three oral medications currently hold FDA approval specifically for painful DPN: duloxetine (sold as Cymbalta), an SNRI antidepressant that works by boosting serotonin and norepinephrine activity in the central nervous system; pregabalin (Lyrica), an anticonvulsant that binds alpha2-delta sites on nerve cells to reduce pain-signaling neurotransmitter release; and tapentadol ER, an opioid-like analgesic. Gabapentin, though not FDA-approved specifically for DPN, is recommended as a first-line option by multiple international guidelines and is widely prescribed. However, these drugs carry real limitations. Pregabalin and gabapentin commonly cause somnolence, dizziness, and cognitive fog — side effects that matter enormously for an older population already at heightened risk for falls and dementia. Duloxetine can cause nausea, fatigue, and withdrawal symptoms if stopped abruptly. For people managing both neuropathic pain and cognitive health, these tradeoffs require careful consideration with a clinician.
None of these drugs reverse the underlying nerve damage; they manage pain only. And for a substantial portion of patients, the pain relief is partial at best. One option that sidesteps the systemic side effect problem is the capsaicin 8% patch, marketed as Qutenza. This topical treatment is FDA-approved specifically for painful DPN of the feet. A single 30-minute application, performed in a clinical setting, desensitizes the TRPV1-expressing nerve fibers in the skin and provides up to three months of sustained local pain relief. Studies show its efficacy for achieving at least a 30% pain reduction is comparable to pregabalin, gabapentin, and duloxetine — without the somnolence, dizziness, nausea, or fatigue. The catch: it requires in-office application, can cause a temporary intense burning sensation during treatment, and does not work for everyone.
Why GLP-1 Drugs Like Semaglutide Are Changing the Equation for Diabetic Feet
The most compelling recent development is not a pain drug at all. GLP-1 receptor agonists — the same class of medications that includes semaglutide (Ozempic, Wegovy) and has dominated headlines for weight loss — appear to dramatically reduce the downstream destruction that diabetic neuropathy causes. A 2025 study using the TriNetX research database compared outcomes in semaglutide users versus non-users over one year and found significant differences across every major foot complication metric. Wound healing complications occurred in 0.19% of semaglutide users versus 0.38% of non-users. Chronic non-healing wounds affected 0.75% versus 1.23%. Amputation rates were 2.34% versus 5.21%.
Wound care needs were 2.42% versus 4.86%. Separately, research on GLP-1 agonists as a class found their use was associated with a 56% lower risk of developing a diabetic foot ulcer compared to insulin over short-term use of 400 days or fewer (hazard ratio: 0.44). GLP-1 use was also linked to lower hospitalization rates, lower mortality, and reduced risk of lower-limb amputation. The mechanisms likely extend beyond simple blood sugar control — GLP-1 receptors are expressed on immune cells, endothelial cells, and neurons, and these drugs appear to reduce systemic inflammation and improve vascular function in ways that support wound healing. For readers of a brain health site, this dual action is particularly relevant. The same anti-inflammatory and neuroprotective properties that may protect feet could also play a role in protecting the brain. Early research into GLP-1 agonists and Alzheimer’s disease is underway, and the overlap between diabetic neuropathy and neurodegeneration is no coincidence — both involve chronic metabolic stress, vascular damage, and inflammatory cascades that destroy nerve tissue.
Comparing Treatment Options — What Actually Works and For Whom
Choosing between treatment approaches depends on what you are trying to accomplish. If the primary goal is pain relief, the FDA-approved oral medications and the capsaicin patch are the direct options. Duloxetine may be preferred for someone who also has depression or anxiety, since it treats both conditions. Pregabalin or gabapentin may suit someone whose pain disrupts sleep, as the sedating effects can be a benefit at bedtime — but a serious liability during the day, especially for older adults at risk for falls or cognitive impairment. The capsaicin patch avoids systemic side effects entirely but requires clinic visits every three months for reapplication. If the goal is preventing foot ulcers, amputations, and the cascade of complications that follows, the conversation shifts. Tight glycemic control remains foundational.
Regular podiatric screening catches problems before they become emergencies. Proper footwear and daily self-examination are low-tech interventions with real impact. But the emerging GLP-1 data suggests that the choice of diabetes medication itself may meaningfully change foot outcomes — meaning a patient on semaglutide may face a fundamentally different risk profile than one on insulin alone, even with similar blood sugar levels. The tradeoff with GLP-1 drugs is cost and access. Semaglutide remains expensive, and insurance coverage varies. Gastrointestinal side effects — nausea, vomiting, diarrhea — are common, particularly during dose escalation. These medications are not currently prescribed for the purpose of preventing foot ulcers; the foot-related benefits are being documented observationally. No randomized controlled trial has yet confirmed a causal relationship between GLP-1 use and reduced amputation risk, and clinicians will rightly point out that semaglutide users may differ from non-users in ways that affect outcomes.
The Recurrence Problem — Why Healing a Foot Ulcer Is Only Half the Battle
One of the most dangerous misconceptions about diabetic foot ulcers is that healing one means the crisis is over. The data says otherwise. After a foot ulcer heals, the recurrence rate is 42% within one year and 65% within five years. The underlying neuropathy and vascular disease do not resolve when the wound closes. The tissue that healed is often weaker and more vulnerable than before. And the behavioral patterns that contributed to the original ulcer — poor-fitting shoes, reduced sensation, inconsistent foot inspection — tend to persist.
This is where the intersection with cognitive health becomes critical. People with diabetes-related cognitive impairment or early dementia are less likely to perform daily foot checks, less likely to notice changes in their feet, and less likely to follow complex wound care regimens. Caregivers managing someone with both diabetic neuropathy and cognitive decline face a genuinely difficult situation: the person most at risk of a foot catastrophe is also the person least equipped to prevent one. Any treatment plan that ignores the cognitive dimension is incomplete. The warning here is straightforward: if you or someone you care for has had a diabetic foot ulcer, treat the period after healing as a high-risk window, not a return to normal. Continued monitoring, proper footwear, and ongoing medical follow-up are not optional. The recurrence statistics make this clear — the ulcer you healed is very likely to come back.
New Devices and Pipeline Drugs to Watch
Beyond medications, a few new approaches are entering the picture. Neuralace Medical recently received FDA clearance for its Axon Therapy device, a noninvasive magnetic peripheral nerve stimulation system designed for painful diabetic neuropathy. The device delivers targeted magnetic stimulation to peripheral nerves without surgery or implants.
While long-term efficacy data is still being gathered, noninvasive nerve stimulation represents a fundamentally different approach — one that does not rely on altering brain chemistry or masking pain signals pharmacologically. On the drug development side, suzetrigine, developed by Vertex Pharmaceuticals, had its New Drug Application accepted by the FDA for priority review in late January 2025 after showing positive Phase 2 results for DPN pain. Suzetrigine targets sodium channel Nav1.8, a pain-specific pathway, which theoretically allows pain relief without the sedation and cognitive effects associated with current treatments. For a population already managing neurological vulnerability, a pain medication that does not add cognitive burden would be a significant advance — if it delivers on that promise in Phase 3 trials and real-world use.
The Bigger Picture — Diabetic Neuropathy as a Whole-Body Nerve Problem
Diabetic peripheral neuropathy is often discussed as a foot problem, but it is fundamentally a nervous system problem. The same metabolic processes that destroy nerve fibers in the feet are at work throughout the body — in the autonomic nerves controlling digestion and heart rate, in the small fibers that regulate blood pressure, and in the brain itself. The connection between type 2 diabetes and increased dementia risk is well established, and it runs through many of the same pathways: chronic inflammation, vascular damage, impaired glucose metabolism in neural tissue. This is why the GLP-1 data matters beyond podiatry.
If these drugs genuinely protect peripheral nerves and improve vascular health in the extremities, researchers are asking whether similar protective effects extend to the central nervous system. The International Diabetes Federation estimates that 40 to 60 million people globally are now affected by diabetic foot ulcers — a sharp increase from estimates of 9 to 26 million in 2015. That trajectory, applied to nerve damage elsewhere in the body, underscores the urgency of finding treatments that do more than manage symptoms. The drugs and devices in development today may ultimately matter as much for the brain as they do for the feet.
Conclusion
Diabetic peripheral neuropathy remains one of the most destructive and underestimated complications of diabetes, affecting up to 70% of people with the disease and driving a cascade of foot ulcers, infections, amputations, and death. Current FDA-approved pain treatments — duloxetine, pregabalin, tapentadol, and the capsaicin 8% patch — offer meaningful but imperfect relief, each with its own tradeoffs. The emerging evidence on GLP-1 receptor agonists, particularly semaglutide, suggests these drugs may reduce foot ulcer risk, wound complications, and amputation rates in ways that go beyond glycemic control alone.
For anyone managing diabetes — whether for themselves or for a loved one with cognitive decline — the practical steps remain essential: regular foot examinations, proper footwear, prompt attention to any wound, and ongoing conversations with medical providers about which medications offer the best overall risk profile. The science is moving, and the options are expanding. But the foundation of preventing diabetic foot destruction is still vigilance, sustained over years, even when healing seems complete.
Frequently Asked Questions
What is the first sign of diabetic peripheral neuropathy in the feet?
The earliest signs are usually tingling, numbness, or a burning sensation in the toes and soles of the feet, often worse at night. Some people notice they can no longer feel temperature changes or minor injuries. Because the onset is gradual, many people do not recognize the symptoms until nerve damage is already significant.
Can diabetic neuropathy be reversed?
In most cases, existing nerve damage cannot be fully reversed. However, tight blood sugar control can slow or stop further progression. Some early-stage nerve damage may partially improve with sustained glycemic management, but once significant fiber loss has occurred, the focus shifts to preventing complications and managing pain.
How does semaglutide help with diabetic foot problems if it is a diabetes drug, not a wound drug?
Semaglutide appears to work through multiple mechanisms beyond blood sugar reduction. It has anti-inflammatory properties, may improve blood vessel function, and GLP-1 receptors are found on immune and endothelial cells involved in wound healing. The 2025 research showing reduced wound complications and amputations in semaglutide users suggests these broader effects contribute to better foot outcomes, though randomized trials are still needed to confirm causation.
Is the capsaicin 8% patch painful to apply?
Yes, most patients experience a burning sensation during the 30-minute application, which is why it is administered in a clinical setting. The discomfort typically subsides within a few days. After that initial period, the patch provides up to three months of pain relief by desensitizing local nerve fibers, without the drowsiness or cognitive effects of oral medications.
Why are diabetic amputation rates rising after years of decline?
Amputation rates have increased by as much as 50% in some regions, with the sharpest rises among young adults and minority populations. Contributing factors include rising diabetes prevalence, barriers to preventive care, insurance gaps, and delayed access to wound management. The trend is particularly alarming because it reverses decades of progress in diabetic foot care.
Does diabetic neuropathy in the feet mean the brain is also at risk?
The metabolic dysfunction that causes peripheral neuropathy — chronic inflammation, vascular damage, impaired glucose metabolism — also affects the central nervous system. Type 2 diabetes is a well-established risk factor for cognitive decline and dementia. While foot neuropathy and brain health are not identical conditions, they share underlying mechanisms, and protecting one may offer clues to protecting the other.
